Skip to content

Two analgesic regimens for the treatment of primary aldosteronism by adrenal artery embolization:An efficacy and safety, proof-of-principle trial

Two analgesic regimens for the treatment of primary aldosteronism by adrenal artery embolization:An efficacy and safety, proof-of-principle trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065253
Enrollment
Unknown
Registered
2022-11-01
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism

Interventions

Group C:Use an analgesic pump for postoperative analgesia
Group E:Perform paravertebral nerve blocks for postoperative analgesia

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients who have been diagnosed with PA; (2) Refusal of drug treatment or failure of drug treatment due to intolerance of adverse reactions, or rejection of adrenalectomy due to surgical risk, or persistent PA after adrenalectomy, but no adrenal insufficiency; (3) PA patients who voluntarily undergo adrenal artery embolization surgery; (4) Male or female patients, age>= 18 years old: 18-75 years old; (5) Informed consent and willingness to be followed-up

Exclusion criteria

Exclusion criteria: (1) History of severe allergy to narcotic drugs or contrast media; (2) complications of severe liver disease; (3) History of myocardial infarction and stent implantation within the past 3 months; (4) renal insufficiency, serum creatinine > 176 mmo/L; (5) pregnancy or breastfeeding; (6) have participated in another clinical trial within the past 3 months; (7) Any serious complications exclude severe heart failure, severe arrhythmia, moderate to severe liver function loss, severe renal insufficiency, pregnancy or breastfeeding, etc.; (8) Speech communication impairment, non-cooperation

Design outcomes

Primary

MeasureTime frame
Blood pressure;Blood pressure;heart rate;oxygen saturation;Respiratory rate;Body mass index;

Countries

China

Contacts

Public ContactTang Ping

The First Affiliated Hospital of Chongqing Medical University

1078355187@qq.com+86 18580741010

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026